Abstracts tagged "Gene Expression"

Abstract Number: 3128 • 2015 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Analysis in Blood and Dermal Fibroblasts from Twin Pairs Discordant for Systemic Sclerosis
Paula S. Ramos¹, Thomas A. Medsger Jr.² and Carol A. Feghali-Bostwick¹, ¹Medicine, Medical University of South Carolina, Charleston, SC, ²Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The etiology and mechanisms underlying the wide variation in disease heterogeneity and severity in systemic sclerosis (SSc) remain unknown. To assess the role of…
Abstract Number: 1072 • 2015 ACR/ARHP Annual Meeting
Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
Robert W Hoffman¹, Joan T Merrill², Marta E. Marta Alarcón Riquelme³, Michelle Petri⁴, Ernst R Dow⁵, Eric Nantz⁶, Laura K Nisenbaum⁵, Krista M Schroeder⁶, Wendy J Komocsar⁶, Narayanan B Perumal⁵, Matthew D Linnik⁶, Guilherme V Rocha⁶ and Richard E Higgs⁶, ¹Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, ²OMRF, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Eli Lilly and Company, Indiananpolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…
Abstract Number: 2098 • 2015 ACR/ARHP Annual Meeting
Prioritizing Likely Causative Genes in Genome-Wide Association Studies (GWAS) Identified Risk Loci for Immune-Mediated Inflammatory Disorders Using Cell-Type Specific Expression Quantitative Loci (eQTL) Information
Elisa Docampo¹, Ming Fang¹, Julia Dmitrieva¹, Emilie Théâtre¹, Mahmoud Elansary¹, Rob Mariman¹, Ann-Stephan Gori¹, Myriam Mni¹, François Crins², Wouter Coppieters², Edouard Louis³ and Michel Georges¹, ¹Unit of Animal Genomics, GIGA-R Université de Liège, Liège, Belgium, ²GenoTranscriptomics platform, GIGA-R Université de Liège, Liège, Belgium, ³Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium
<h1> Background/Purpose: </h1> Immune-mediated inflammatory disorders (IMIDs) share many genetic risk factors. Pleiotropy may exist at different levels and most of the underlying mechanisms are…
Abstract Number: 3259 • 2015 ACR/ARHP Annual Meeting
Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signatrue
Shervin Assassi¹, Maureen D Mayes¹, Claudia Pedroza², Jeffrey T. Chang², Daniel E. Furst³, Leslie J. Crofford⁴, Richard Nash⁵, Peter McSweeney⁵, Mary Ellen Csuka⁶, Ellen Goldmuntz⁷, Lynette Keyes-Elstein⁸, Paul Wallace⁹ and Keith Sullivan¹⁰, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²University of Texas Medical School at Houston, Houston, TX, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Medicine, Vanderbilt University, Nashville, TN, ⁵Colorado Blood Cancer Institute, Denver, CO, ⁶Rheum/Med Coll of Wisconsin, Med Coll of Wisconsin, Milwaukee, WI, ⁷NIAID, National Institutes of Health, Bethesda, MD, ⁸Rho Federal Systems, Inc., Chapel Hill, NC, ⁹Roswell Park, Buffalo, NY, ¹⁰Duke University, Durham, NC
Background/Purpose: Previous clinical trials have suggested that immunoablation followed by autologous hematopoietic cell transplantation (HCT) can lead to clinical improvements in systemic sclerosis (SSc). However,…
Abstract Number: 1099 • 2015 ACR/ARHP Annual Meeting
Single Cell RNA-Seq Analysis of Citrullinated Alpha-Enolase Peptide-Specific B Cells in RA
Yogita Ghodke-Puranik¹, Na Zhang², Jessica M. Dorschner¹, Anna Shmagel³, Zhongbo Jin¹, Philip Titcombe⁴, Timothy B. Niewold¹ and Daniel Mueller⁵, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Medicine, University of Minnesota Medical School, Minneapolis, MN, ³Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ⁴University of Minnesota Medical School, Minneapolis, MN, ⁵Medicine/Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: The high prevalence of citrullinated protein antibodies and improvement following rituximab anti-CD20 therapy both suggest that B cells are important in the pathogenesis of…
Abstract Number: 2100 • 2015 ACR/ARHP Annual Meeting
Hypomethylation in Enhancer and Promoter Regions of Interferon Regulated Genes in Multiple Tissues Is Associated with Primary Sjögren’s Syndrome
Juliana Imgenberg-Kreuz¹, Johanna K Sandling^1,2, Jonas Carlsson Almlöf¹, Jessica Nordlund¹, Linnea Signér², Katrine B Norheim³, Roald Omdal³, Majia-Leena Eloranta², Lars Rönnblom², Ann-Christine Syvänen¹ and Gunnel Nordmark², ¹Molecular Medicine and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ³Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Epigenetic modifications have emerged as important contributing factors in the pathogenesis of autoimmune diseases, including primary Sjögren’s syndrome (pSS), and may act as a…
Abstract Number: 1116 • 2015 ACR/ARHP Annual Meeting
Decreased Expression of Negative Regulators of Toll-like Receptor Signaling and Increased TLR7 Responsiveness in Expanded IgD- CD27- B Cells from Systemic Lupus Erythematosus Patients
Scott Jenks¹, Benjamin Barwick² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Emory University, Altanta, GA, ³Medicine, Emory University, Atlanta, GA
Background/Purpose: B cell homeostasis is perturbed in SLE patients; in particular many patients with active disease have a large expansion of IgD- CD27- B cells…
Abstract Number: 2136 • 2015 ACR/ARHP Annual Meeting
Identification of Synovial Fibroblast Subsets That Define Pathology in Rheumatoid Arthritis
Fumitaka Mizoguchi¹, Kamil Slowikowski^2,3, Sook Kyung Chang¹, Deepak A. Rao⁴, Hung Nguyen¹, Erika H. Noss⁵, Brandon E. Earp⁶, Philip E. Blazar⁶, John Wright⁶, Barry P. Simmons⁶, Nir Hacohen^7,8,9, Peter A. Nigrovic^1,10, Soumya Raychaudhuri^2,3,11 and Michael B. Brenner¹, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Divison of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Broad Institute of MIT and Harvard, Cambridge, MA, ⁸Massachusetts General Hospital, Charlestown, MA, ⁹Harvard Medical School, Boston, MA, ¹⁰Division of Immunology, Boston Children's Hospital, Boston, MA, ¹¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Synovial fibroblasts play crucial roles in the pathogenesis of rheumatoid arthritis (RA). They expand as part of the pannus, mediate degradation of cartilage, amplify…
Abstract Number: 1132 • 2015 ACR/ARHP Annual Meeting
Altered Histone 3 Dynamics at the Matrix Metalloproteinase 1 (MMP1) Transcription Start Site Contributes to MMP1 Suppression in Betaine Supplemented Synovial Fibroblasts in Rheumatoid Arthritis
Selene Glück¹, Niharika Gaur¹, Michelle Trenkmann^1,2, Emmanuel Karouzakis¹, Fangfang Sun¹, Christoph Kolling³, Beat A. Michel¹, Renate E. Gay¹, Steffen Gay¹, Michel Neidhart¹ and Mojca Frank Bertoncelj¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, University Zurich, Zurich, Switzerland, ²St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ³Schulthess Clinic, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Synovial fibroblasts (SF) produce elevated levels of matrix degrading enzymes, including matrix metalloproteinase 1 (MMP1), in the joints of rheumatoid arthritis (RA) patients, leading…
Abstract Number: 2151 • 2015 ACR/ARHP Annual Meeting
Inhibition of Myeloid-Associated Gene Expression in Skin Biopsy Samples of Systemic Sclerosis Patients Treated with Tocilizumab
Thierry Sornasse¹, Haiyin Chen¹, Lisa Rice², Giuseppina Stifano², Angelika Jahreis¹, Jeffrey Siegel¹ and Robert Lafyatis², ¹Genentech, South San Francisco, CA, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis. Tocilizumab (TCZ), an IL-6Rα inhibitor,…
Abstract Number: 1142 • 2015 ACR/ARHP Annual Meeting
Joint Specific Function of Synovial Fibroblasts – Integrating Positional Transcriptomes and Anatomic Patterns of Arthritis
Mojca Frank Bertoncelj¹, Michelle Trenkmann¹, Kerstin Klein¹, Emmanuel Karouzakis¹, Christoph Kolling², Andrew Filer³, Christopher Buckley⁴, Beat A. Michel¹, Renate E. Gay¹, Steffen Gay¹ and Caroline Ospelt¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, University Zurich, Zurich, Switzerland, ²Upper Extremity Dept., Schulthess Clinic Zurich, Zurich, Switzerland, ³University of Birmingham, Birmingham, United Kingdom, ⁴University of Birmingham, Rheumatology Research Group, Birmingham, United Kingdom
Background/Purpose: Synovial fibroblasts (SF) profoundly influence physiological and pathological processes in the joint such as reaction to inflammatory stimuli and production of extracellular matrix. We…
Abstract Number: 2174 • 2015 ACR/ARHP Annual Meeting
Neutrophils in Primary Antiphospholipid Syndrome Are Characterized By a Prominent Activated Phenotype and Uniquely Remodeled Chromatin Architecture
Patrick Coit, Srilakshmi Yalavarthi, Jason S. Knight and Amr H. Sawalha, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by recurrent thrombotic events, pregnancy complications, and the presence of antiphospholipid antibodies. The pathogenesis of…
Abstract Number: 1163 • 2015 ACR/ARHP Annual Meeting
Dynamic Regulation of Enhancers and Super-Enhancers in Rheumatoid Arthritis Synovial Finroblasts
Sung-Ho Park¹, Christopher Sohn¹, Konstantinos Loupasakis², Angela Lee³, Eugenia Giannopoulou¹, Lionel B. Ivashkiv³ and George D. Kalliolias¹, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ³Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Enhancers are regulatory elements that modulate transcriptional rates of genes. Super-enhancers (SupE) are extremely large enhancers associated primarily with highly expressed genes that have…
Abstract Number: 2462 • 2015 ACR/ARHP Annual Meeting
Altered Expression of IL-10 Family Cytokines in Chronic Recurrent Multifocal Osteomyelitis Result in Enhanced Inflammasome Activation
Sigrun Hofmann¹, Angela Rösen-Wolff¹, Hermann Girschick², Henner Morbach³ and Christian Hedrich⁴, ¹Children's Hospital Dresden, Dresden, Germany, ²Children's Hospital, Berlin, Germany, ³Children's Hospital Würzburg, Würzburg, Germany, ⁴Pediatric Rheumatology and Immunology, Children's Hospital Dresden, Dresden, Germany
Background/Purpose: Chronic recurrent multifocal osteomyelitis (CRMO) is the most severe presentation of the autoinflammatory bone disorder chronic nonbacterial osteomyelitis (CNO). The pathophysiology of CNO remains…
Abstract Number: 1243 • 2015 ACR/ARHP Annual Meeting
Identification of the Gene Expression Signatures Predicting the Responses to Three Biologics (infliximab, tocilizumab, and abatacept) in Rheumatoid Arthritis
Seiji Nakamura¹, Hiroshi Iijima¹, Yuko Hata², Yohei Ishizawa², Chun Ren Lim², Ryo Matoba², Katsuya Suzuki³, Koichi Amano⁴ and Tsutomu Takeuchi³, ¹Kanagawa, DNA Chip Research Inc., Yokohama, Japan, ²DNA Chip Research Inc., Yokohama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Background/Purpose: Employing genome-wide gene transcription on a unified platform, to identify molecular signatures for predicting therapeutic effects for rheumatoid arthritis (RA) with three biologics, infliximab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].